Medicare Holds Hospital Outpatient Payment For Drugs At ASP+4% For 2010
This article was originally published in The Pink Sheet Daily
Executive Summary
Draft rule for Part B hospital outpatient prospective payment system in 2010 goes against advisory panel recommendation to increase reimbursement to average sales price plus 6 percent. Other changes affecting drugs and biologicals are proposed.
You may also be interested in...
CMS Methodology, Not Industry Complaints, Brings Proposed Hospital Part B Outpatient Drug Reimbursement Back To ASP+6% in 2011
Agency calls rate a "coincidental outcome" in its proposed update to the Medicare hospital outpatient prospective payment system for 2011.
CMS Methodology, Not Industry Complaints, Brings Proposed Hospital Part B Outpatient Drug Reimbursement Back To ASP+6% in 2011
Agency calls rate a "coincidental outcome" in its proposed update to the Medicare hospital outpatient prospective payment system for 2011.
Zevalin Completes Transition To ASP-Based Reimbursement In OPPS
Spectrum Pharmaceuticals' radiopharmaceutical Zevalin (ibritumomab tiuxetan) will be reimbursed like other Medicare Part B drugs administered in the hospital outpatient setting, according to the final outpatient prospective payment update for 2010